HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $46.00 price target on the stock.

ITOS has been the topic of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday. Wells Fargo & Company lowered their price target on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th.

iTeos Therapeutics Trading Up 6.0 %

ITOS stock opened at $7.26 on Thursday. iTeos Therapeutics has a 12-month low of $6.67 and a 12-month high of $18.75. The business’s 50-day moving average is $7.54 and its 200 day moving average is $9.55. The stock has a market cap of $265.24 million, a price-to-earnings ratio of -2.30 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. As a group, equities analysts forecast that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new position in shares of iTeos Therapeutics during the 3rd quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in iTeos Therapeutics during the fourth quarter worth about $42,000. Virtus ETF Advisers LLC boosted its holdings in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the last quarter. Forefront Analytics LLC purchased a new stake in shares of iTeos Therapeutics in the 4th quarter valued at approximately $85,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth approximately $85,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.